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Abstract
For precision medicine and personalized treatment, we need to identify predictive
markers of disease. We focus on Alzheimer’s disease (AD), where magnetic reso-
nance imaging scans provide information about the disease status. By combining
imaging with genome sequencing, we aim at identifying rare genetic markers
associated with quantitative traits predicted from convolutional neural networks
(CNNs), which traditionally have been derived manually by experts. Kernel-based
tests are a powerful tool for associating sets of genetic variants, but how to opti-
mally model rare genetic variants is still an open research question. We propose a
generalized set of kernels that incorporate prior information from various annota-
tions and multi-omics data. In the analysis of data from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI), we evaluate whether (i) CNNs yield precise and
reliable brain traits, and (ii) the novel kernel-based tests can help to identify loci
associated with AD. The results indicate that CNNs provide a fast, scalable and
precise tool to derive quantitative AD traits and that new kernels integrating domain
knowledge can yield higher power in association tests of very rare variants.
1 Introduction
In this study, we focus on Alzheimer’s disease (AD) as outcome of interest, which is a progressive
neurodegenerative disease, appears late-onset and sporadic in most cases, and is the main cause of
dementia in the elderly. As the cognitive symptoms emerge years after the appearance of brain atrophy
and exhibit close correlation with the structural changes, brain magnetic resonance imaging (MRI)
scans provide a direct way to obtain informative quantitative traits, and fast automated approaches are
necessary for large-scale studies. AD has a high estimated heritability of 74% [1] and a prevalence of
4.4% in Europe [2]. However, the biological pathways underlying AD have not been well-understood
and there is yet no known cure. Hence, the identification of AD markers for early detection and as
targets for treatment is important.
For the detection of causal genetic loci, recent sequencing efforts allow in-depth analyses of rare
variants in large cohorts, and kernel-based gene-level tests have been proposed for the analysis
[3, 4, 5, 6, 7]. They derive similarity scores between samples in the form of a kernel matrix which
is computed on a particular genomic locus or functional unit in the genome. Then, kernel-based
variance-component test statistics are derived that yield robust and powerful tests. Kernel functions
provide a highly flexible way to model genetic variation. However, their full capabilities have not
been leveraged and existing approaches still provide suboptimal performance for the analysis of
sequencing data [8], where the overwhelming majority of genetic variation is extremely rare. Hence
extensions to the existing methods are warranted that leverage the full power of kernels to aggregate
the signal of very rare single nucleotide variants (SNVs).
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Figure 1: Illustration of association tests using kernel maps.
Our contributions in this paper are in two areas. First, we use a convolutional neural network (CNN) to
derive quantitative traits from MRI scans in the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
and evaluate and compare the obtained traits to traits obtained by the popular yet computationally
expensive FreeSurfer software [9]. Second, we propose novel kernels for association tests of rare
genetic variants that incorporate prior biological knowledge from annotations and multi-omics
measures. We perform association analyses between these novel kernels computed on sequencing
data and CNN-derived traits as well as other traits to identify genetic loci associated with AD.
1.1 Related work
The association of a set of m genetic markers with a quantitative trait Y with n observations can be
tested in a linear mixed model of the form
Y = Xα+ Zβ +Gγ + ε, (1)
where X is a covariate design matrix with fixed effects α, β ∼ N (0, σ2z I) are random effects
of the SNVs in design matrix Z accounting for population stratification, I is the identity matrix,
γ ∼ N (0, σ2g I) are random effects of the m SNVs of interest in the n ×m design matrix G, and
ε ∼ N (0, σ2ε) are error terms. Hence
Y ∼ N (Xα, σ2zZZT + σ2gK + σ2ε I) (2)
where the n× n kernel matrix K = GGT describes the similarity between individuals based on the
m SNVs of interest. The association of the m SNVs (i.e. H0 : σ2g = 0 vs. H0 : σ
2
g > 0) can be
tested using score or likelihood ratio tests. Binary or count traits can be analyzed similarly.
Popular kernel-based tests include FaST-LMM-Set [5, 6], the sequence kernel association test (SKAT,
[3]) and optimal SKAT (SKAT-O, [4]), which are based on weighted linear kernels K = GWWTGT
[3, 5, 6], or a linear combination of weighted linear and collapsing kernels [4]. Newer approaches [7]
derive further data-adaptive combinations of linear, quadratic, IBS, and collapsing kernels. However,
all these kernels provide suboptimal performance for the analysis of very rare genetic variants. For
example, linear kernels yield uninformative similarity measures (i.e., diagonal kernel matrices for
singletons, which are variants with only one observed copy of the minor allele) and collapsing kernels
often yield unspecific signals and aggregate noise.
2 New kernel-based tests for very rare genetic variants
To leverage the full power of kernels computing similarities in high-dimensional Hilbert space,
whereto genetic variants are mapped through a potentially infinite-dimensional basis function φ, we
consider the more general linear mixed model
Yi = Xiα+ Ziβ + φ(Gi)γ + εi, i = 1 . . . n. (3)
Here, β and γ are normally distributed random effects. After integrating out β, γ and , it follows that
Y is normally distributed with covariance σ2zZZ
T + σ2gK + σ
2
εI, where we have defined the kernel
matrix K := φ(G)φ(G)T . In this model, established tests [4, 5, 6] can be used to test the association
between sets of SNVs and the phenotype, see Figure 1 for an illustration.
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2.1 Examples of new kernels
Let G be the matrix of the m SNVs of interest. We define a class of n× n kernel matrices K as
K = GVWWTV TGT (4)
where different instances are obtained by setting the m×m weight and similarity matrices W , V to
the identity, to the matrices outlined below, or any combination of these. See Appendix A for details.
Incorporate annotations Set W as the diagonal matrix W = diag(√w1, . . . ,√wm) where wj ≥
0, j = 1, . . . ,m, is the weight of the j-th SNV based on the minor allele frequency (MAF), genomic
position, or functional annotation from PolyPhen2 [10], RegulomeDB [11], or others. Set the
elements ij of V to (i) describe the similarity of SNVs i and j in terms of genomic closeness, or (ii)
indicate whether SNVs i and j have a (or the same) functional annotation.
Incorporate information from available omics data Set W = diag(√w1, . . . ,√wm) where
wj ≥ 0, j = 1, . . . ,m, (i) is the -log10 p-value of the association test of the j-th SNV with omics
data, e.g. gene expression levels of the respective gene (cis-eQTL), or (ii) indicates for each of these
p-values if they are < α, where α is pre-specified constant, e.g. α = 0.05. Set the elements ij of V
to be indicators whether SNVs i and j both have p-value < α.
3 Application: analysis of ADNI study
In the application, we analyzed whole-genome-sequencing data, gene expression measures, MRI data
as well as AD biomarkers in n = 556 participants from ADNI, which is a longitudinal study to detect
biomarkers and risk factors for AD [12, 13].
In a first step, we designed a 3-dimensional CNN comprising seven convolutional layers followed
by a max pooling layer and a final fully-connected layer to predict the volume of the 3rd ventricle
from the MRI scans (see Figure 2 for an illustration and see Appendix B, Figure S1 for details).
To evaluate the approach, we chose the 3rd ventricle, as we found that the ventricular regions were
displayed with a higher contrast and presumably easier to identify. The CNN predicted volume was
then used as a quantitative trait in the following genetic association analyses, and evaluated against
the predictions by the FreeSurfer software. Both models where trained on a dual Intel Xeon 6148
workstation equipped with an NVidia Titan-V graphics card.
In the main genetic association analysis we analyzed 17,013 (quality-controlled, biallelic, missingness
<5%, of any MAF) SNVs in 125 genes in the 1Mbp region around the APOE gene on chromosome
19, similar to the study in [14], to investigate rare variants in a genomic region where several
common variants have been associated with AD. We performed cross-sectional association tests of
these 125 genes with 9 different AD traits (peptides CSF Aβ, t-tau, p-tau, and the provided brain
volumes of entorhinal cortex, hippocampus, medial temporal lobe, ventricles, 3rd ventricle predicted
by FreeSurfer, and 3rd ventricle predicted from the CNN) adjusting for the covariates age, gender,
education, ethnicity, and APOE4 allele. The association tests were performed based on kernels with
different combinations of V and W in Appendix A and using standard SKAT and SKAT-O.
64 Ch32 Ch1 Ch 64 Ch 128 Ch  128 Ch 256 Ch 512 Ch 512 Ch Fully-Connected 
Layer
Output
Convolution using a 3x3x3 
Filter with strides of 1x1x1 
Down-Convolution using a 2x2x2 
Filter with strides of 2x2x2 
Max Pooling using a 2x2x2 Filter
96 x 109 x 96 48 x 54 x 48 24 x 27 x 24 12 x 13 x 12 6 x 6 x 6
Figure 2: Overview of 3D convolutional neural network.
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Table 1: Minimum p-values from the 125 association tests (of the 125 genes) for each respective trait
and test. Tests are based on SKAT, SKAT-O and the new kernels 1 (identity V , MAF + omics W ), 2
(genomic distance + omics V , omics W ), 3 (PolyPhen2 + omics V , PolyPhen2 + omics + MAF W ),
testing each trait and gene separately. For each trait (row), the smallest p-value is indicated in red.
Trait SKAT-O SKAT New Kernel 1 New Kernel 2 New Kernel 3
CSF t-tau 9.1 ×10−5 5.8 ×10−5 5.2 ×10−5 6.4 ×10−4 4.0 ×10−4
CSF p-tau 1.5 ×10−3 9.3 ×10−4 8.5 ×10−4 1.2 ×10−3 1.9 ×10−3
CSF Aβ 4.9 ×10−3 9.9 ×10−3 4.9 ×10−3 2.1 ×10−3 1.7 ×10−3
Entorhinal cortex 7.0 ×10−4 3.3 ×10−4 4.2 ×10−4 1.6 ×10−2 3.4 ×10−3
Hippocampus 6.6 ×10−2 3.7 ×10−2 3.8 ×10−2 5.6 ×10−4 2.5 ×10−2
Med-temporal lobe 1.1 ×10−3 3.7 ×10−3 1.4 ×10−3 2.3 ×10−2 4.6 ×10−3
Ventricles 1.5 ×10−2 9.3 ×10−3 1.0 ×10−2 9.6 ×10−4 5.5 ×10−3
FreeS 3rd Ventricle 6.8 ×10−2 6.5 ×10−2 8.0 ×10−2 3.4 ×10−2 5.1 ×10−3
CNN 3rd Ventricle 1.9 ×10−2 5.9 ×10−2 5.9 ×10−2 1.7 ×10−2 2.0 ×10−2
3.1 Results
The 125 genes contained on average 220 SNVs (min = 1, max = 1759). Of the 17,013 SNVs, 7575
were singletons, 1740 doubletons, and 12,337 SNVs had MAF < 0.01. 24 participants had dementia,
338 mild cognitive impairment, 194 were cognitive normal (see Table S1 for descriptive statistics).
In an evaluation of the predicted volume of the 3rd ventricle, CNN and FreeSurfer predictions
showed a high correlation (Pearson r = 0.92, see Figure S2). For small/large volumes, compared to
FreeSurfer, CNN slightly over-/underestimated the volume, which we expect to disappear with larger
training data. On the other hand, CNN was much faster (1 second versus 16 hours per scan).
In the main genetic association analyses, a first comparison showed that analyses using the CNN-
predicted trait as outcome generally yielded similar and often smaller p-values compared to the
FreeSurfer-predicted trait (Figures S3-S4). Preliminary comparisons of the new kernels indicated
that the three kernels reported in Table 1 yielded often the smallest p-values in gene-based tests,
hence they are reported here. Tests based on the new kernel 1 yielded consistently smaller or similar
p-values for the top genes compared to SKAT and SKAT-O for 8 out of 9 traits (Table 1). More
detailed comparisons (Figure S5) indicated that while often the same genes were identified with
smallest p-value by tests based on the new kernel 1 and by SKAT or SKAT-O, the new kernel 1 also
yielded different candidate genes that would not have been identified by SKAT or SKAT-O (and vice
versa). The new kernels 2 and 3 yielded sometimes larger but also sometimes much smaller p-values.
Using a Bonferroni correction (for the 125 tests) of the p-values of the new kernel-based tests, we
identified 3 candidate genes for AD with adjusted p-values 0.007, 0.05, 0.07: PVR for CSF t-tau,
SIX5 for entorhinal cortex and PVRL2 for hippocampus.
4 Discussion
The empirical analyses indicated that (i) CNNs provide a precise, fast and scalable tool to derive
quantitative traits from MRI scans and that (ii) new kernels integrating domain knowledge and omics
data constitute a promising approach for the analysis of very rare variants. There is previous evidence
for the association of the identified genes with AD [15, 16, 17, 18] to support our findings, and of
note, the p-values are much smaller using the new kernels here compared to regular kernels [14].
Limitations of the current analyses are that only few functional annotations are available for rare
SNVs, and that only a basic control for population stratification was used. In the interpretation of the
results regarding their biological relevance, it can be noted that the analyses were adjusted for the
risk factor APOE4, so that the identified genes and SNVs represent markers with independent effects
on AD. Future research can investigate kernels measuring the similarity between the bivariate allelic
sequences directly and data-adaptive optimal combinations of different kernels.
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Supplementary material
A Details on new kernels
Let n be the number of observations and m the number of SNVs of interest. Define the kernel K
as K = GVWWTV TGT in equation (4) by setting the m × m matrices W and V to I or the
following.
Consider the weight matrices W = diag(
√
w1, . . . ,
√
wm) where
1. wj ∼ Beta(MAFj , 1, 25) where Beta is the probability density function of the beta
distribution and MAFj is the minor allele frequency of SNV j
2. wj is an indicator whether SNV j has a functional annotation in e.g. the PolyPhen2 database
3. wj is a numeric encoding of the functional annotation of SNV j, for example, in the
PolyPhen2 database:
wj =

0 if SNVj is not annotated
1 if SNVj has annotation "benign"
2 if SNVj has annotation "possibly damaging"
3 if SNVj has annotation "probably damaging"
4. wj is the -log10 p-value from a hypothesis test of the association between SNV j and a
variable Z providing relevant information about its biological function, e.g. where Z is the
gene expression of the gene in which the SNV lies
5. wj is the sum of 1 and an indicator variable whether SNV j is associated with a variable
Z providing relevant information about its biological function as in the bullet point above,
e.g. evaluating whether the p-value from a hypothesis test of the association between SNV j
with a variable Z is smaller than 0.05
6. wj is the product of the wj in bullet points (1 and 4) or (1 and 5)
7. wj is the sum of the wj in bullet points (2 or 3) and (4 or 5)
8. wj is the sum of the wj in bullet points (2 or 3) and 6
with j = 1, . . . ,m.
Consider the m×m matrices V describing the similarity of SNVs where
1. Vij = similarity of SNVs i and j in terms of genomic closeness:
Vij =
{
1 if i = j
1/dij else
where dij is the genomic distance between SNVs i and j in base pairs
2. Vij = indicator whether SNVs i and j both have a functional annotation:
Vij =
{
1 if i = j
1 if SNVs i, j are annotated
0 else.
3. Vij = indicator whether SNVs i and j have the same functional annotation
Vij =
{
1 if i = j
1 if SNVs i, j have the same annotation
0 else.
4. Vij = indicator whether SNVs i and j have p-value < specified cutoff value α
Vij =
{
1 if i = j
1 if SNVs i, j both have p-value < α
0 else.
where the p-values of SNVs i, j are from association tests with a variable Z that provides
relevant information about their biological function, e.g. where Z is the gene expression of
the gene in which the SNVs lie
5. V is the product of the matrices in bullet points (1 and (2 or 3)), (1 and 4), or (4 and (2 or 3))
6. V is the product of the matrices in bullet points 1 and (2 or 3) and 4
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B Details on convolutional neural networks
Model architecture The model architecture is illustrated in Figure 2, and in more detail in Figure
S1. We designed a CNN made of a sequence of seven convolutional layers followed by a max
pooling layer and a fully-connected layer. We used two types of convolutional layers: Regular and
Down-Convolution. Regular convolutional layers comprised a 3 x 3 x 3 convolutional operation with
1 x 1 x 1 strides. The down-convolutional layers comprised a 2 x 2 x 2 convolutional operation with
2 x 2 x 2 strides. Each convolutional layer was followed by a Rectified Linear Unit non-linearity
[19]. After the last convolutional layer, we used a max pooling layer with a filter size of 2 x 2 x 2.
Subsequently, this layer was converted into a fully-connected layer, followed by the output layer
containing a single node with a linear activation function.
Model implementation The MRI scans were standardized to the spatial resolution of 1 x 1 x 1
millimeters and the size of 256 x 256 x 256 voxels. Additionally, for computational efficiency, they
were cropped and down-sampled to 96 x 109 x 96 voxels.
The model was trained on 2100 MRI scans (from 411 subjects) for 200 epochs with the loss function
set to the mean absolute error using the Adaptive Moment Estimation optimizer [20], a learning rate
of 10−4 and a 3D spatial drop out regularization of 0.9.
Hyperparameter tuning was carried out on a validation dataset comprising 550 scans of 129 subjects
that all had MRI data but did not have genetic data available so that they could not be included in the
main analysis. The final evaluation was done on the test set including the 556 subjects of the main
analysis that had all MRI, genetic, and gene expression data available. The model performance on
the test set is visualized in Figure S2.
Computational comparison with FreeSurfer Both models where trained on a dual 20 core Intel
Xeon 6148 workstation with 768GB RAM equipped with an NVidia Titan-V graphics card. CNN
computations made use of GPU optimization, taking 1 second for the prediction of the volume of the
third ventricle per MRI scan. FreeSurfer, which did not utilize the GPU, took 16 hours per MRI scan.
C Supplementary tables and figures
Table S1: Descriptive statistics of the n = 556 individuals in the analyzed sample from the ADNI
study. Shown are absolute frequencies for categorical variables, and mean (standard deviation) for
quantitative measures.
Measures Descriptive Statistics
Sample size 556
Age, years 72.9 (7.0)
Gender
female 250
male 306
Ethnic group
hispanic/latino 10
not hispanic/latino 545
unknown 1
Education length, years 16.1 (2.8)
APOE ε4 allele
homozygot minor allele 331
heterozygot 186
homozygot major allele 39
Cognitive status
cognitive normal 194
mild cognitive impairment 338
dementia 24
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input: InputLayer input: (None, 96, 109, 96, 1) output: (None, 96, 109, 96, 1) 
 
 
 
conv_1: Conv3D input: (None, 96, 109, 96, 1) output: (None, 96, 109, 96, 32) 
 
 
 
conv_2: Conv3D input: (None, 96, 109, 96, 32) output: (None, 96, 109, 96, 64) 
 
 
 
Down_3_dc0: Conv3D input: (None, 96, 109, 96, 64) output: (None, 48, 54, 48, 64) 
 
 
 
conv_4: Conv3D input: (None, 48, 54, 48, 64) output: (None, 48, 54, 48, 128) 
 
 
 
Down_5_dc0: Conv3D input: (None, 48, 54, 48, 128) output: (None, 24, 27, 24, 128) 
 
 
 
conv_6: Conv3D input: (None, 24, 27, 24, 128) output: (None, 24, 27, 24, 256) 
 
 
 
Down_7_dc0: Conv3D input: (None, 24, 27, 24, 256) output: (None, 12, 13, 12, 512) 
 
 
 
spatial_dropout3d: SpatialDropout3D input: (None, 12, 13, 12, 512) output: (None, 12, 13, 12, 512) 
 
 
 
max_pooling3d: MaxPooling3D input: (None, 12, 13, 12, 512) output: (None, 6, 6, 6, 512) 
 
 
 
flatten: Flatten input: (None, 6, 6, 6, 512) output: (None, 110592) 
 
 
 
FC_last: Dense input: (None, 110592) output: (None, 1) 
Figure S1: Graphical visualization of the 3D convolutional neural network model in Keras. Shown
are input and output of the different layers, and the respective voxels and channels. For example, the
input volume had 96 × 109 × 96 voxels and 1 channel. As all computations were done in one batch,
the batch size was not specified (noted as "None" in the graph).
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Figure S2: Scatterplot of the volume of the third ventricle prediction by FreeSurfer (x axis) and the
CNN (y axis). All predictions are represented as z scores. In addition, the diagonal is printed for a
comparison of both predictions.
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Figure S3: Scatterplot of the -log10 p-values from association tests of the 125 genes with the volume
of the third ventricle predicted by FreeSurfer (x axis) and CNN (y axis) as outcome, using SKAT-O
for testing. In addition, the diagonal is printed for a comparison of both tests.
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Figure S4: Scatterplot of the -log10 p-values from association tests of the 125 genes with the volume
of the third ventricle predicted by FreeSurfer (x axis) and CNN (y axis), using the new kernel-based
test 1 (identity V , MAF + omics W ). In addition, the diagonal is printed for a comparison of both
tests.
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Figure S5: Scatterplot of the -log10 p-values from association tests of the 125 genes using SKAT (x
axis) and the new kernel-based test 1 (identity V , MAF + omics W , y axis), for each of the 9 traits in
separate panels. In addition, the diagonal is printed for a comparison of both tests.
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